AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts

Faga described the remaining royalty-focused entity as anchored by two assets: royalties on GSK’s Jemperli and potential economics from imsidolimab, which Anaptys has outlicensed to Vanda.The biopharma business is expected to house three clinical-stage programs, and “most, if not all” employees would move into the new company, which will have a new name and remain publicly traded. Faga said the new biopharma entity would be capitalized with at least enough cash to reach key readouts in the CD122 program “pl ...